Bayer Aktiengesellschaft (SWX:BAYN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 51.36B +105.5% |
| Revenue (ttm) | 43.36B -0.2% |
| Net Income | -1.37B |
| EPS | -1.36 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 11.83 |
| Dividend | 0.10 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 600 |
| Open | 43.46 |
| Previous Close | 43.46 |
| Day's Range | 43.46 - 43.46 |
| 52-Week Range | 32.75 - 48.69 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
German chemicals lobby lifts 2026 sales forecast, but warns recovery remains elusive
German chemicals lobby VCI on Thursday raised its 2026 industry sales forecast on the back of higher prices, but warned the temporary boost from supply disruptions tied to the Iran war had faded.
Bayer’s Sunharbo approved by FDA to reduce risk of stroke
The company states: “Bayer (BAYRY) announced that the U.S. Food and Drug Administration has approved SUNHARBO(R) (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...
Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Rece...
A new type of blood thinner approved on Monday is the first shown in testing to prevent repeat strokes without significantly increasing a person's bleeding risk
Bayer's drug, when added to blood thinners, helped reduce the risk of second strokes without increased bleeding risks.
Bayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity
PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America's Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce...
Bayer seeks bigger role in fast-growing Latin American biologicals market
Bayer said on Wednesday it will launch 17 new biological products in Latin America by 2030, including biopesticides and crop performance enhancers, as it targets a market growing faster than the gl...
Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific S...
Bayer Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month organic sales rose 3% and adjusted EBITDA 7%, prompting higher FY guidance for adjusted EBITDA, free cash flow and debt. Pharma growth strengthened, while litigation payments and crop-market pressures remained key uncertainties.
Bayer Aktiengesellschaft Quarterly report: Q3 2026
Bayer Aktiengesellschaft has published its Q3 2026 quarterly earnings report on November 3, 2026.
Bayer Aktiengesellschaft Slides: Q3 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Bayer says ‘operationally on track’ to deliver full-year commitments
Bayer (BAYRY) is operationally on track to deliver its full-year commitments at the nine-month mark, while also aiming to capitalize on improved trends as the year draws to a close.
Bayer Aktiengesellschaft Earnings Call Transcript: Q3 2026
Nine-month organic sales rose 3% and adjusted EBITDA 7%, with Pharma leading Q3. Guidance increased for adjusted EBITDA and free cash flow, while litigation payments kept free cash flow negative.
Bayer Aktiengesellschaft Earnings release: Q3 2026
Bayer Aktiengesellschaft released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Bayer Raises Earnings Outlook on Pharma Recovery
The German group posted a recovery in its pharma arm after strong demand for key drugs allowed it to offset market pressures at its agricultural and consumer-health divisions.
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Bayer raises 2026 profit outlook
German pharmaceuticals and agriculture group Bayer (BAYGn.DE), opens new tab raised its 2026 profit outlook on Tuesday, citing a better-than-expected performance at the company's pharmaceuticals busi...
China approves Bayer blood thinner asundexian
China's drug regulator said on Monday it approved the blood thinner asundexian from Bayer , a potential boost for the German drugmaker in the world's second-largest pharmaceutical market as it moves
Bayer Gets in China Its First Global Approval for Stroke Prevention Drug
The decision hands Bayer the first ever approval for a Factor XIa inhibitor, which aim to slow the activity of a protein that regulates how the body forms clots without increasing the risk of bleeding...
ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence
WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence.
Bayer to Present New Cardiac Amyloidosis and Heart Failure Data at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that one late-breaking presentation along with five posters across its cardiovascular programs will be featured at the Heart Failur...
Bayer partners with actress Melissa Joan Hart to increase awareness of Lynkuet
Bayer (BAYRY) announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet 60mg capsules, Bayer’s FDA-approved, hormone-free prescription treatment...
Actress and Menopause Advocate Melissa Joan Hart Partners with Bayer to Raise Awareness about Lynkuet® (elinzanetant), a Prescription Treatment for Moderate to Severe Hot Flashes due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced a partnership with actress and menopause advocate Melissa Joan Hart to increase awareness about Lynkuet® (elinzanetant) 60mg capsules, Bayer's FD...
Bayer announces FDA acceptance of Kerendia sNDA
Bayer (BAYRY) announced that the FDA accepted the company’s supplemental new drug application, or sNDA, for Kerendia, which is being investigated for the treatment of adults with chronic kidney diseas...
U.S. FDA Accepts Bayer's Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted the company's supplemental New Drug Application (sNDA) for KERENDIA® (fin...